Search results for "Thrombin time"

showing 10 items of 26 documents

Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms

2005

Abstract Background. Prothrombin time is a benchmark for functional assessment in cirrhosis and Factor VII levels (FVII), crucial in determining the prothrombin time, are genetically determined. Methods. We have evaluated the prothrombin time, a number of haemostatic variables synthesised by the liver (FII, FV, FVII and activated FVII, AT and fibrinogen) and two polymorphisms of the FVII gene (5′F7 and 353R/Q) in: (a) patients with liver cirrhosis ( n  = 118), (b) patients with chronic hepatitis ( n  = 102) and (c) controls ( n  = 100). Results. By one-way analyses of variance, the prothrombin time and the mean levels of the FII, FV, FVIIc, FVIIa, and AT were statistically different between…

Liver Cirrhosismedicine.medical_specialtyCirrhosisGenotypeLiver CirrhosiFibrinogenChronic liver diseasechemistry.chemical_compoundhemic and lymphatic diseasesInternal medicineGenotypemedicineHumansAlleleAllele frequencyAllelesHepatitis ChronicProthrombin timeAllelePolymorphism GeneticHepatologyFactor VIImedicine.diagnostic_testbusiness.industryGastroenterologyFactor VIImedicine.diseaseEndocrinologychemistryCase-Control StudiesProthrombin TimebusinessCase-Control Studiemedicine.drugHuman
researchProduct

SARS CoV2 infection _The longevity study perspectives

2021

Graphical abstract

MaleAgingssRNA single-stranded RNARFLP restriction fragment length polymorphismHSPs heat shock proteinsReviewPTMs post-translational modificationsSevere Acute Respiratory SyndromeBiochemistryHIV-1 human immunodeficiency virus-1TNF-α tumor necrosis factor-αEC endothelial cells0302 clinical medicineFluAV influenza A virusI insertionMedicineIFN-γ interferon-γDIC disseminated intravascular coagulationPCR Polymerase Chain Reactionmedia_commonAged 80 and overLongevityRBD receptor-binding domainNeurologyLongevity modelMI myocardial infarctionNK natural killerhPIV2 human parainfluenza virus type 2media_common.quotation_subjectResearching genetic basis of resistance and potential pharmacological targetsLongevityDBP diastolic blood pressureNF-Kb nuclear transcription factor kBRANTES regulated upon activation normal T cell expressed and secretedMphi human macrophages03 medical and health sciencesCox 2 cyclooxygenase 2ORF open reading framePT prothrombin timeSettore MED/05 - Patologia ClinicaHumansMolecular BiologyInflammatory genesARDS acute respiratory distress syndromeNO nitric oxideD deletionCpGIs CpG islandsT2DM type 2 diabetes mellitusmedicine.diseaseFDP fibrin degradation products030104 developmental biologySARS CoV2 severe acute respiratory syndrome Coronavirus 2 virusImmunologyBMI body max indexItalian nonagenarians/centenariansRSV respiratory syncytial virusComplication030217 neurology & neurosurgeryMAPK mitogen-activated protein kinaseIP-10 IFN-γ -Inducible Protein 1040301 basic medicineAT1R activity of angiotensin 1 receptorsDCs dentritic cellsSSCP single strand conformation polymorphismACE/DD polymorphism of the angiotensin converting enzymeFGF21 fibroblast growth factor 21TLR4 toll-like receptor 4NAD nicotinamide adenine dinucleotideACE angiotensin-I converting enzymeAT2R activity of angiotensin 2 receptorsCOVID-19 Coronavirus disease 2019Respiratory distressACE2 angiotensin converting enzyme 2MKP-1 mitogen-activated protein kinase phosphatase-1 ()PD protease domainSNP single nucleotide polymorphismEH essential hypertensionTNFR tumor necrosis factor receptorINR international normalized ratio of the prothrombin timePAI-1 plasminogen activator inhibitor-1Ang angiotensinLPS lipopolysaccharideMCP1 monocyte chemoattractant protein-1medicine.symptomaPTT partial thromboplastin timeBiotechnologyDUSP1 dual specificity phosphatase 1Coronavirus disease 2019 (COVID-19)PC prostate cancerRAS renin-angiotensin aldosterone systemCCR5Δ32 genetic variant of chemokine receptorCOVID-19 Researching genetic basis of resistance and potential pharmacological targets Italian nonagenarians/centenarians Longevity modelAsymptomaticSARS-1 severe acute respiratory syndrome virus 1SIRT-1 Sirtuin 1Th1 t-helper lymphocyte type 1Immune systemROS reactive oxygen speciesTGF-β transforming growth factor betaET-1 endothelin-1ComputingMethodologies_COMPUTERGRAPHICSADAM-17 metallopeptidase domain 17business.industrySARS-CoV-2SBP systolic blood pressureCOVID-19HDACs histone deacetylasesComorbidityImmune Systembusiness5-LO lipoxygenase 5Ageing Research Reviews
researchProduct

Natural and engineered carboxy-terminal variants: decreased secretion and gain-of-function result in asymptomatic coagulation factor VII deficiency.

2012

We report 2 asymptomatic homozygotes for the nonsense p.R462X mutation affecting the carboxy-terminus of coagulation factor VII (FVII, 466 aminoacids). FVII levels of 3-5% and 2.7 ± 0.4% were found in prothrombin time-based and activated factor X (FXa) generation assays with human thromboplastins. Noticeably, FVII antigen levels were barely detectable (0.7 ± 0.2%) which suggested a gain-of-function effect. This effect was more pronounced with bovine thromboplastin (4.8 ± 0.9%) and disappeared with rabbit thromboplastin (0.7 ± 0.2%). This suggests that the mutation influences tissue factor/FVII interactions. Whereas the recombinant rFVII-462X variant confirmed an increase in specific activit…

MaleProteasesHeterozygoteFactor VII DeficiencyEnzyme-Linked Immunosorbent AssayFVIIBiologymedicine.disease_causeThromboplastinTissue factorchemistry.chemical_compoundCarboxy-terminalhemic and lymphatic diseasesmedicineFACTOR VII DEFICIENCY MOLECULAR VARIANTSThromboplastinMissense mutationAnimalsHumanscardiovascular diseasesChildBlood CoagulationProthrombin timeMutationmedicine.diagnostic_testFactor VIIHomozygoteHematologyFactor VIIMiddle AgedMolecular biologyAsymptomatic; Carboxy-terminal; FVII; Mutation;AsymptomaticchemistryCoagulationCodon NonsenseMutationMutagenesis Site-DirectedProthrombin TimeCattleFemaleRabbitsOriginal Articles and Brief Reports
researchProduct

Sudden sensorineural hearing loss: is there a relationship between routine haematological parameters and audiogram shapes?

2016

Objective: To investigate the relationship between haematological routine parameters and audiogram shapes in patients affected by sudden sensorineural hearing loss (SSNHL). Design: A retrospective study. All patients were divided into four groups according to the audiometric curve and mean values of haematological parameters (haemoglobin, white blood cell, neutrophils and lymphocytes relative count, platelet count, haematocrit, prothrombin time, activated partial thromboplastin time, fibrinogen and neutrophil-to-lymphocite ratio) of each group were statistically compared. The prognostic role of blood profile and coagulation test was also examined. Study sample: A cohort of 183 SSNHL patient…

MaleTime FactorsNeutrophilshaematological parameterAudiologyLanguage and LinguisticsHemoglobinsLeukocyte Count0302 clinical medicineHearingLymphocytes030223 otorhinolaryngologyHematologic Testsmedicine.diagnostic_testComplete blood countAudiogramSudden sensorineural hearing lossMiddle AgedSettore MED/32 - AudiologiaTreatment OutcomeSettore MED/31 - Otorinolaringoiatriamedicine.anatomical_structureHematocrit030220 oncology & carcinogenesisCohortAudiometry Pure-ToneFemalePartial Thromboplastin TimeSteroidsmedicine.symptomPartial thromboplastin timeAdultBlood PlateletsLinguistics and Languagemedicine.medical_specialtyHearing lossHearing Loss Sensorineural03 medical and health sciencesSpeech and HearingAudiogram shapePredictive Value of TestsWhite blood cellmedicineHumansBlood CoagulationRetrospective StudiesProthrombin timePlatelet Countbusiness.industryFibrinogenAuditory ThresholdRetrospective cohort studyRecovery of FunctionHearing Loss Suddenaudiogram shape; haematological parameters; Sudden sensorineural hearing lossProthrombin TimebusinessBiomarkersInternational Journal of Audiology
researchProduct

Factors responsible for interindividual differences in the dose requirement of phenprocoumon

1987

The total and unbound plasma concentrations of phenprocoumon and the prothrombin complex activity were determined in 51 patients on phenprocoumon. A 7-fold difference in the dosing rate (10-70 micrograms/kg/day) was required to maintain the prothrombin complex activity at 11-30% of normal. The variation in dosing requirement was mainly due to interindividual differences in the intrinsic clearance of phenprocoumon and only to a minor degree to differences in sensitivity to it. On average patients with myocardial infarction required only 2/3 of the daily dose of phenprocoumon of post cardiac surgery patients and patients with thrombosis and emboli. That difference appeared to be due to higher…

Malemedicine.medical_specialtymedicine.drug_classIndividualityPhenprocoumonPharmacokineticsInternal medicinemedicineHumansPharmacology (medical)Myocardial infarctionDosingPharmacologyChemistryCoronary ThrombosisAnticoagulant4-HydroxycoumarinsGeneral MedicineMiddle Agedmedicine.diseaseThrombosisCardiac surgeryEndocrinologyPhenprocoumonProthrombin TimeCardiologyFemaleProtein Bindingmedicine.drugSurgical patientsEuropean Journal of Clinical Pharmacology
researchProduct

Bleeding prophylaxis in a child with cleft palate and factor VII deficiency: a case report.

2006

Bleeding prophylaxis in a child with cleft palate and factor VII deficiency: a case report. Pirrello R, Siragusa S, Giambona C, D'Arpa S, Cordova A, Moschella F. Source Dipartimento di Discipline Chirurgiche ed Oncologiche, Sezione di Chirurgia Plastica e Ricostruttiva, Università di Palermo, Palermo, Italy. Abstract The association between factor VII deficiency and cleft palate has never been described. The case of a child with cleft palate and factor VII deficiency who successfully underwent palatoplasty is described in this article. To allow surgical treatment, through maintenance of a normal prothrombin time, the patient was given 15 microg/kg of recombinant factor VIIa every 12 hours, …

Malemedicine.medical_specialtymedicine.medical_treatmentFactor VII DeficiencyPremedicationBlood Loss SurgicalFactor VIIaPostoperative HemorrhageEfficacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedicineHumans030223 otorhinolaryngologyFactor VII deficiencyProthrombin timemedicine.diagnostic_testFactor VIIbiologybusiness.industryCoagulantsPalate030206 dentistryPerioperativePlastic Surgery ProceduresRecombinant ProteinsSurgeryCleft PalatePalatoplastyEl NiñochemistryOtorhinolaryngologyRecombinant factor VIIaAnesthesiaChild Preschoolbiology.proteinFACTOR VII DEFICIENCY CLEFT PALATE BLEEDING PROPHYLAXISProthrombin TimeOral SurgerybusinessThe Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association
researchProduct

Permeabilit�ts�nderungen durch Dicumarol unabh�ngig von �nderungen der Prothrombinzeit

1950

Bei Mausen wurde nach Dicumarol per os in Dosen von 0,05–1 mg/g zirka 1–25 Std nach der Dicumarol-Gabe die Prothrombinzeit bestimmt und kurz danach die Odembildung der Hinterbeine bei der Durchstromung mit Tyrodelosung untersucht. In den meisten Fallen war innerhalb der ersten 7 Std die Prothrombinzeit unverandert, dagegen war eine erhohte Kapillarpermeabilitat eingetreten. Von 11 Std aufwarts war die Prothrombinzeit fast immer erhoht, wahrend die Gefaspermeabilitat in der Mehrzahl der Falle nicht mehr erhoht war. Nach akut nicht todlich wirkenden Gaben von 0,1–0,3 mg/g Dicumarol war die Permeabilitat nach Ablauf von 7 Std in der Mehrzahl der Falle sogar vermindert. Aus den Versuchen ist zu…

PharmacologyGynecologyProthrombin timemedicine.medical_specialtymedicine.diagnostic_testChemistryPharmacology toxicologymedicineGeneral MedicineNaunyn-Schmiedebergs Archiv f�r Experimentelle Pathologie und Pharmakologie
researchProduct

Evidence for Impaired Hepatic Vitamin K1 Metabolism in Patients Treated with N-Methyl-Thiotetrazole Cephalosporins

1984

SummaryIn 8 patients on no oral intake and with parenteral alimentation, administration of cephalosporins with N-methyl-thiotetrazole side chain (moxalactam, cefamandole), was associated with prolongation of prothrombin time, appearance in the circulation of descarboxy-prothrombin (counter immunoelectrophoresis and echis carinatus assay) and diminution of protein C. Acute administration of 10 mg vitamin Ki was followed by the transient appearance of vitamin K1 2,3-epoxide, indicating an impaired hepatocellular regeneration of vitamin K1 from the epoxide. Impaired hepatic vitamin K1 metabolism, tentatively ascribed to the N-methyl-thiotetrazole group, is one (but possibly not the only) cause…

Prothrombin timeDiminutionVitaminmedicine.medical_specialtymedicine.diagnostic_testmedicine.drug_classbusiness.industryCephalosporinHematologyMetabolismchemistry.chemical_compoundEndocrinologychemistryInternal medicinemedicineCefamandolebusinessProtein CMoxalactammedicine.drugThrombosis and Haemostasis
researchProduct

Manejo perioperatorio de los anticoagulantes orales directos en cirugía urgente y sangrado. Monitorización y tratamiento hemostático

2015

There is an almost unanimous consensus on the management of the direct new oral anticoagulants, dabigatran, rivaroxaban, and apixaban in elective surgery. However, this general consensus does not exist in relation with the direct new oral anticoagulants use in emergency surgery, especially in the bleeding patient. For this reason, a literature review was performed using the MEDLINE-PubMed. An analysis was made of the journal articles, reviews, systematic reviews, and practices guidelines published between 2000 and 2014 using the terms "monitoring" and "reversal". From this review, it was shown that the routine tests of blood coagulation, such as the prothrombin time and activated partial th…

Prothrombin timeRivaroxabanmedicine.diagnostic_testbusiness.industryPerioperativeCritical Care and Intensive Care MedicineDabigatranAnesthesiology and Pain MedicineCoagulationAnesthesiamedicineApixabanElective surgerybusinessmedicine.drugPartial thromboplastin timeRevista Española de Anestesiología y Reanimación
researchProduct

Clinical characteristics of COVID-19 patients in Latvia under low incidence in Spring 2020

2020

ABSTRACTBackgroundCOVID-19 is a new infectious disease with severe disease course and high mortality in some groups. Blood tests on admission to the hospital can be useful for stratification of patients and timely correction. Our study investigated the clinical features of COVID-19 patients in Latvia and differences in blood tests in groups with different disease severity.MethodsThe retrospective study included 100 patients hospitalized in Riga East Clinical University Hospital in Spring 2020. The severity of the disease course was classified by the presence of pneumonia and its combination with respiratory failure. We have assessed blood cells’ count, hemoglobin, hematocrit, erythrocyte se…

Prothrombin timemedicine.medical_specialtyCreatininemedicine.diagnostic_testTroponin Tbusiness.industryMortality rateRenal functionHematocritGastroenterologychemistry.chemical_compoundRespiratory failurechemistryInternal medicineErythrocyte sedimentation ratemedicinebusiness
researchProduct